Hafner, M.; Herold, T.R.; Kufner, A.; Asani, B.; Anschütz, A.; Eckardt, F.; Priglinger, S.G.; Schiefelbein, J.
Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes. J. Clin. Med. 2025, 14, 2454.
https://doi.org/10.3390/jcm14072454
AMA Style
Hafner M, Herold TR, Kufner A, Asani B, Anschütz A, Eckardt F, Priglinger SG, Schiefelbein J.
Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes. Journal of Clinical Medicine. 2025; 14(7):2454.
https://doi.org/10.3390/jcm14072454
Chicago/Turabian Style
Hafner, Michael, Tina R. Herold, Alexander Kufner, Ben Asani, Andreas Anschütz, Franziska Eckardt, Siegfried G. Priglinger, and Johannes Schiefelbein.
2025. "Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes" Journal of Clinical Medicine 14, no. 7: 2454.
https://doi.org/10.3390/jcm14072454
APA Style
Hafner, M., Herold, T. R., Kufner, A., Asani, B., Anschütz, A., Eckardt, F., Priglinger, S. G., & Schiefelbein, J.
(2025). Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes. Journal of Clinical Medicine, 14(7), 2454.
https://doi.org/10.3390/jcm14072454